EUVIMEDEUVIMED entdecken
Crossref

Molecular Risk Stratification for Decision-Making Among Patients With Breast Cancer Eligible to Omit Radiation Therapy

Shoshana J Rosenzweig, Lillian A Boe, Hannah Y Wen, Boris Mueller, Diana Roth O'Brien, George E Naoum, Zeinab Abou Yehia, J Isabelle Choi, Emma Hahesy, Mahmoud El-Tamer, Simon N Powell, Atif J Khan und 1 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026-10 · 126 (2) · 379-387

DOI: 10.1016/j.ijrobp.2026.03.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-10. Verfasst von Shoshana J Rosenzweig und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Decision Making. Die Arbeit nennt 24 Literaturangaben. Gefördert von: NIH NCI, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Radiation therapy (RT) following breast-conserving surgery reduces the risk of recurrence for early-stage breast cancer. A subset of patients with favorable clinical and pathologic characteristics can safely omit RT with a modest increase in recurrences, yet without survival implications. We sought to evaluate whether molecular risk profiling among such patients could further stratify them into (1) a higher-risk subgroup that may be inappropriate for RT omission and (2) an exceedingly favorable subgroup that might more strongly consider RT omission. METHODS AND MATERIALS: Using a prospectively maintained institutional database, we evaluated patients aged ≥65 years who underwent breast-conserving surgery for early-stage, estrogen receptor-positive breast cancer (ie, patients putatively eligible for RT omission). Patients were stratified by clinicopathologic features and Oncotype DX Recurrence Score (RS; ≤25 vs >25) and were evaluated for oncologic outcomes and survival by receipt of RT. RESULTS: The overall cohort comprised 1587 patients: 92% had RS ≤25 (n = 1455) and 8% had RS >25 (n = 132). With a median follow-up of 74.4 months, the cumulative incidence of local recurrence was low throughout and did not significantly differ between those with RS ≤25 vs >25 (6-year rate 1.9% vs 0.8%; P = .5). Among those who did not undergo RT (n = 350), patients with RS >25 (n = 19) did not have a significantly higher incidence of local recurrence than patients with RS ≤25 (6-year rate 5.6% vs 4.2%; P = .5). CONCLUSIONS: Among patients ≥65 years of age who underwent breast-conserving surgery for early-stage estrogen receptor-positive breast cancer, Oncotype DX RS did not further refine recurrence risk estimates for RT decision-making beyond the findings of landmark RT omission trials. Although the number of patients with Oncotype DX RS >25 who omitted RT was limited in this study, this subgroup did not exhibit a significantly higher risk than their low-molecular-risk counterparts, suggesting that risk score need not necessarily disqualify select patients who seek to forgo adjuvant RT. Prospective analyses with larger sample sizes will further elucidate the role of molecular assays in guiding RT decision-making across risk strata.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm Recurrence, LocalDecision MakingHumansFemaleAgedMastectomy, SegmentalRisk AssessmentAged, 80 and overReceptors, Estrogen

Substanzen

Receptors, Estrogen

Autor:innen und Institutionen

  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: BRAUNSTL@mskcc.org.

Förderung

  • NIH NCI
  • National Institutes of Health

Zitieren

APA

Rosenzweig, S. J., Boe, L. A., Wen, H. Y., Mueller, B., Roth O'Brien, D., Naoum, G. E., Abou Yehia, Z., Choi, J. I., Hahesy, E., El-Tamer, M., Powell, S. N., Khan, A. J., & Braunstein, L. Z. (2026). Molecular Risk Stratification for Decision-Making Among Patients With Breast Cancer Eligible to Omit Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics, 126(2), 379-387. https://doi.org/10.1016/j.ijrobp.2026.03.032

Vancouver

Rosenzweig SJ, Boe LA, Wen HY, Mueller B, Roth O'Brien D, Naoum GE, et al. Molecular Risk Stratification for Decision-Making Among Patients With Breast Cancer Eligible to Omit Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 2026;126(2):379-387. doi:10.1016/j.ijrobp.2026.03.032

BibTeX
@article{Rosenzweig2026,
  author = {Rosenzweig, Shoshana J and Boe, Lillian A and Wen, Hannah Y and Mueller, Boris and Roth O'Brien, Diana and Naoum, George E and Abou Yehia, Zeinab and Choi, J Isabelle and Hahesy, Emma and El-Tamer, Mahmoud and Powell, Simon N and Khan, Atif J and Braunstein, Lior Z},
  title = {Molecular Risk Stratification for Decision-Making Among Patients With Breast Cancer Eligible to Omit Radiation Therapy},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  volume = {126},
  number = {2},
  pages = {379--387},
  doi = {10.1016/j.ijrobp.2026.03.032}
}
Kostenlos starten →